These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25456002)

  • 1. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.
    Pengo V; Testa S; Martinelli I; Ghirarduzzi A; Legnani C; Gresele P; Passamonti SM; Bison E; Denas G; Jose SP; Banzato A; Ruffatti A
    Thromb Res; 2015 Jan; 135(1):46-9. PubMed ID: 25456002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
    Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
    Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus anticoagulant, high levels of anticardiolipin, and anti-beta2-glycoprotein I antibodies are associated with chronic thromboembolic pulmonary hypertension.
    Martinuzzo ME; Pombo G; Forastiero RR; Cerrato GS; Colorio CC; Carreras LO
    J Rheumatol; 1998 Jul; 25(7):1313-9. PubMed ID: 9676762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid antibodies: evaluation of the thrombotic risk.
    Devreese KM
    Thromb Res; 2012 Oct; 130 Suppl 1():S37-40. PubMed ID: 23026657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus.
    Woo KS; Kim KE; Kim JM; Han JY; Chung WT; Kim KH
    Korean J Lab Med; 2010 Feb; 30(1):38-44. PubMed ID: 20197721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies.
    Neville C; Rauch J; Kassis J; Solymoss S; Joseph L; Belisle P; Subang R; Chang ER; Fortin PR
    Rheumatology (Oxford); 2006 Sep; 45(9):1116-20. PubMed ID: 16510527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile.
    Pengo V; Ruffatti A; Del Ross T; Tonello M; Cuffaro S; Hoxha A; Banzato A; Bison E; Denas G; Bracco A; Padayattil Jose S
    J Thromb Haemost; 2013 Aug; 11(8):1527-31. PubMed ID: 23601766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation.
    Forastiero R
    Lupus; 2014 Oct; 23(12):1252-4. PubMed ID: 25228718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity.
    Ruffatti A; Tonello M; Del Ross T; Cavazzana A; Grava C; Noventa F; Tona F; Iliceto S; Pengo V
    Thromb Haemost; 2006 Sep; 96(3):337-41. PubMed ID: 16953276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
    Pengo V; Ruffatti A; Legnani C; Gresele P; Barcellona D; Erba N; Testa S; Marongiu F; Bison E; Denas G; Banzato A; Padayattil Jose S; Iliceto S
    J Thromb Haemost; 2010 Feb; 8(2):237-42. PubMed ID: 19874470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?
    Bardin N; Alessi MC; Dignat-George F; Vague IJ; Sampol J; Harlé JR; Sanmarco M
    Immunobiology; 2007; 212(7):557-65. PubMed ID: 17678713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis.
    Marie I; Jouen F; Hellot MF; Levesque H
    Br J Dermatol; 2008 Jan; 158(1):141-4. PubMed ID: 18028496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.
    Swadzba J; De Clerck LS; Stevens WJ; Bridts CH; van Cotthem KA; Musial J; Jankowski M; Szczeklik A
    J Rheumatol; 1997 Sep; 24(9):1710-5. PubMed ID: 9292792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.
    Musial J; Swadzba J; Motyl A; Iwaniec T
    J Rheumatol; 2003 Apr; 30(4):723-30. PubMed ID: 12672190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.
    Lockshin MD; Kim M; Laskin CA; Guerra M; Branch DW; Merrill J; Petri M; Porter TF; Sammaritano L; Stephenson MD; Buyon J; Salmon JE
    Arthritis Rheum; 2012 Jul; 64(7):2311-8. PubMed ID: 22275304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
    Kassis J; Neville C; Rauch J; Busque L; Chang ER; Joseph L; Le Comte M; Subang R; Fortin PR
    Thromb Haemost; 2004 Dec; 92(6):1312-9. PubMed ID: 15583739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.